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PREAMBLE
Incorporation of new study results, medications, or de-
vices that merit modification of existing clinical prac-
tice guideline recommendations, or the addition of new 
recommendations, is critical to ensuring that guidelines 
reflect current knowledge, available treatment options, 
and optimum medical care . To keep pace with evolving 
evidence, the American College of Cardiology (ACC)/
American Heart Association (AHA) Task Force on Clini-
cal Practice Guidelines (“Task Force”) has issued this 
focused update to revise existing guideline recommen-
dations on the basis of recently published study data . 
This update has been subject to rigorous, multilevel 
review and approval, similar to the full guidelines . For 
specific focused update criteria and additional meth-
odological details, please see the ACC/AHA guideline 
methodology manual .1
Modernization
Processes have evolved over time in response to 
published reports from the Institute of Medicine2,3 
and ACC/AHA mandates,4–7 leading to adoption of a 
“knowledge byte” format . This process entails delinea-
tion of a recommendation addressing a specific clinical 
question, followed by concise text (ideally <250 words 
per recommendation) and hyperlinked to supportive 
evidence . This approach better accommodates time 
constraints on busy clinicians, facilitates easier access 
to recommendations via electronic search engines and 
other evolving technology, and supports the evolution of 
guidelines as “living documents” that can be dynamically 
updated as needed .
Class of Recommendation and Level of Evidence
The Class of Recommendation (COR) and Level of Evi-
dence (LOE) are derived independently of each other 
according to established criteria . The COR indicates 
the strength of recommendation, encompassing the es-
timated magnitude and certainty of benefit of a clinical 
action in proportion to risk . The LOE rates the quality 
of scientific evidence supporting the intervention on the 
basis of the type, quantity, and consistency of data from 
clinical trials and other sources (Table 1) . Recommenda-
tions in this focused update reflect the new 2015 COR/
LOE system, in which LOE B and C are subcategorized 
for the purpose of increased granularity .1,7,8
Relationships With Industry and other Entities
The ACC and AHA exclusively sponsor the work of 
guideline writing committees (GWCs) without commer-
cial support, and members volunteer time for this ac-
tivity . Selected organizations and professional societies 
with related interests and expertise are invited to par-
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ticipate as partners or collaborators . The Task Force 
makes every effort to avoid actual, potential, or per-
ceived conflicts of interest that might arise through re-
lationships with industry or other entities (RWI) . All GWC 
members and reviewers are required to fully disclose 
current industry relationships or personal interests, be-
ginning 12 months before initiation of the writing effort . 
Management of RWI involves selecting a balanced GWC 
and requires that both the chair and a majority of GWC 
members have no relevant RWI (see Appendix 1 for the 
definition of relevance) . GWC members are restricted 
with regard to writing or voting on sections to which RWI 
apply . Members of the GWC who recused themselves 
from voting are indicated and specific section recusals 
are noted in Appendixes 1 and 2 . In addition, for trans-
parency, GWC members’ comprehensive disclosure in-
formation is available as an Online Supplement (http://
circ .ahajournals .org/lookup/suppl/doi:10 .1161/
CIR .0000000000000404/-/DC1) . Comprehensive dis-
closure information for the Task Force is also available 
at http://www .acc .org/guidelines/about-guidelines-and-
clinical-documents/guidelines-and-documents-task-forces . 
The Task Force strives to avoid bias by selecting ex-
perts from a broad array of backgrounds representing 
different geographic regions, genders, ethnicities, intel-
lectual perspectives, and scopes of clinical activities .
Intended Use
Guidelines provide recommendations applicable to pa-
tients with or at risk of developing cardiovascular dis-
ease . The focus is on medical practice in the United 
States, but guidelines developed in collaboration with 
other organizations may have a broader target . Although 
guidelines may be used to inform regulatory or payer 
decisions, the intent is to improve quality of care and 
align with patients’ interests . The guidelines are reviewed 
annually by the Task Force and are official policy of the 
ACC and AHA . Each guideline is considered current un-
less and until it is updated, revised, or superseded by a 
published addendum .
Related Issues
For additional information pertaining to the methodol-
ogy for grading evidence, assessment of benefit and 
harm, shared decision making between the patient and 
clinician, structure of evidence tables and summaries, 
standardized terminology for articulating recommen-
dations, organizational involvement, peer review, and 
policies regarding periodic assessment and updating of 
guideline documents, we encourage readers to consult 
the ACC/AHA guideline methodology manual .1
Jonathan L. Halperin, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Clinical Practice 
Guidelines
1. INTRoDUCTIoN
The scope of this focused update is limited to address-
ing recommendations on duration of dual antiplatelet 
therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients 
with coronary artery disease (CAD) . Recommendations 
considered are those in 6 guidelines: “2011 ACCF/AHA/
SCAI Guideline for Percutaneous Coronary Intervention”,9 
“2011 ACCF/AHA Guideline for Coronary Artery Bypass 
Graft Surgery”,10 “2012 ACCF/AHA/ACP/AATS/PCNA/
SCAI/STS Guideline for the Diagnosis and Management 
of Patients With Stable Ischemic Heart Disease”,11,12 
“2013 ACC/AHA Guideline for the Management of ST-El-
evation Myocardial Infarction”,13 “2014 ACC/AHA Guide-
line for Non–ST-Elevation Acute Coronary Syndromes”,14 
and “2014 ACC/AHA Guideline on Perioperative Cardio-
vascular Evaluation and Management of Patients Under-
going Noncardiac Surgery” .15
The impetus for this focused update review is 11 stud-
ies16–27 of patients treated with coronary stent implanta-
tion (predominantly with drug-eluting stents [DES]) as-
sessing shorter-duration or longer-duration DAPT, as well 
as a large, randomized controlled trial (RCT) of patients 
1 to 3 years after myocardial infarction (MI) assessing 
the efficacy of DAPT compared with aspirin monothera-
py .28 These studies were published after the formulation 
of recommendations for duration of DAPT in prior guide-
lines . The specific mandate of the present writing group 
is to evaluate, update, harmonize, and, when possible, 
simplify recommendations on duration of DAPT .
Although there are several potential combinations of 
antiplatelet therapy, the term and acronym DAPT has 
been used to specifically refer to combination antiplate-
let therapy with aspirin and a P2Y12 receptor inhibitor 
(clopidogrel, prasugrel, or ticagrelor) and will be used 
similarly in this focused update . Recommendations in 
this focused update on duration of DAPT, aspirin dosing 
in patients treated with DAPT, and timing of elective non-
cardiac surgery in patients treated with percutaneous 
coronary intervention (PCI) and DAPT supersede prior 
corresponding recommendations in the 6 relevant guide-
lines . These recommendations for duration of DAPT ap-
ply to newer-generation stents and, in general, only to 
those not treated with oral anticoagulant therapy . For the 
purposes of this focused update, patients with a history 
of acute coronary syndrome (ACS) >1 year prior who 
have since remained free of recurrent ACS are consid-
ered to have transitioned to stable ischemic heart dis-
ease (SIHD) and are addressed in the section on SIHD . 
Issues and recommendations with regard to P2Y12 inhibi-
tor “pretreatment,” “preloading,” and loading are beyond 
the scope of this document but are addressed in other 
guidelines .9,14,29
This focused update is designed to function both 
as a standalone document and to serve as an update 
to the relevant sections on duration of DAPT in the 6 
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clinical practice guidelines, replacing relevant text, fig-
ures, and recommendations . Thus, by necessity, there is 
some redundancy in different sections of this document . 
When possible, the “knowledge byte” format was used 
for recommendations . In some cases, the complexity of 
this document required a modification of the knowledge 
byte format, with several interrelated recommendations 
grouped together, followed by concise associated text 
(<250 words of text per recommendation) .
1.1. Methodology and Evidence Review
Clinical trials published since the 2011 PCI guideline9 and 
the 2011 coronary artery bypass graft (CABG) guide-
line,10 published in a peer-reviewed format through De-
cember 2015, were reviewed by the Task Force to iden-
tify trials and other key data that might affect guideline 
recommendations . The information considered important 
enough to prompt updated recommendations is included 
in evidence tables in the Data Supplement .
Table 1. Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, 
Treatments, or Diagnostic Testing in Patient Care* (Updated August 2015)
D
ow
nloaded from
 http://ahajournals.org by on August 13, 2019
Focused Update on Duration of Dual Antiplatelet Therapy
CLINICAL STATEM
ENTS 
AND GUIDELINES
Circulation. 2016;134:e123–e155. DOI: 10.1161/CIR.0000000000000404 September 6, 2016 e127
In accord with recommendations by the Institute of 
Medicine2,3 and the ACC/AHA Task Force Methodology 
Summit,1,6 3 critical (PICOTS-formatted; population, in-
tervention, comparison, outcome, timing, setting) ques-
tions were developed to address the critical questions 
related to duration of DAPT . These 3 critical questions 
were the basis of a formal systematic review and evalu-
ation of the relevant study data by an Evidence Review 
Committee (ERC) .30 Concurrent with this process, writ-
ing group members evaluated study data relevant to the 
numerous current recommendations in the 6 guidelines, 
including topics not covered in the 3 critical questions 
(eg, DAPT after CABG) . The findings of the ERC and the 
writing group members were formally presented and dis-
cussed, and then modifications to existing recommen-
dations were considered . Recommendations that are 
based on a body of evidence that includes a systematic 
review conducted by the ERC are denoted by the su-
perscript SR (eg, LOE B-R SR) . See the ERC systematic 
review report, “Duration of Dual Antiplatelet Therapy: A 
Systematic Review for the 2016 ACC/AHA Guideline Fo-
cused Update on Duration of Dual Antiplatelet Therapy 
in Patients With Coronary Artery Disease,” for the com-
plete evidence review report .30
1.2. organization of the Writing Group
Recommendations on duration of DAPT are currently in-
cluded in 6 clinical practice guidelines, which are interre-
lated and overlapping because they address the manage-
ment of patients with CAD . Therefore, the writing group 
consisted of the chairs/vice chairs and/or members of 
all 6 guidelines, representing the fields of cardiovascular 
medicine, interventional cardiology, cardiac surgery, inter-
nal medicine, and cardiovascular anesthesia, as well as 
expertise in trial design and statistical analysis .
1.3. Review and Approval
This focused update was reviewed by the writing com-
mittee members from the 6 guidelines; by 5 official re-
viewers from the ACC and AHA; 2 reviewers each from the 
American Association for Thoracic Surgery, American 
College of Emergency Physicians, American Society of 
Anesthesiologists, Preventive Cardiovascular Nurses As-
sociation, Society for Cardiovascular Angiography and 
Interventions, Society of Cardiovascular Anesthesiolo-
gists, and the Society of Thoracic Surgeons; and by 23 
additional content reviewers . Reviewers’ RWI information 
is published in this document (Appendix 2) .
This document was approved for publication by the 
governing bodies of the ACC and the AHA and was en-
dorsed by the American Association for Thoracic Sur-
gery, American Society of Anesthesiologists, Preventive 
Cardiovascular Nurses Association, Society for Car-
diovascular Angiography and Interventions, Society of 
Cardiovascular Anesthesiologists, Society of Thoracic 
Surgeons, and Society for Vascular Surgery .
2. CRITICAL QUESTIoNS AND SySTEMATIC  
REvIEW FINDINGS
2.1. Critical Questions on Duration of DAPT
The 3 critical (PICOTS-formatted) questions on DAPT 
duration are listed in Table 2 . Most contemporary 
studies of DAPT have compared either shorter (3 to 6 
months)17–21 or longer (18 to 48 months)16,22–26 dura-
tion of therapy with 12 months of DAPT, which is the 
recommended or minimal duration of therapy for most 
patients in ACC/AHA9,13,14 and European Society of Cardi-
ology31–33 guidelines published between 2011 and 2014 . 
Recommendations based on the findings from the criti-
cal question–focused systemic reviews are provided in 
Sections 4 to 8 of the present document .
2.2. Studies of Shorter-Duration DAPT After Stent 
Implantation
Five RCTs of patients treated with elective DES implan-
tation have compared shorter-duration (3 to 6 months) 
DAPT with 12 months of DAPT17–21 (Data Supplement 1) . 
The trials primarily enrolled low-risk (non-ACS) patients, 
with only a small proportion having had a recent MI . The 
main endpoints of these noninferiority trials were compos-
ite ischemic events (or net composite events) and stent 
thrombosis . These studies, as well as several meta-anal-
yses34–37 and an analysis by the ERC,30 did not find any 
increased risk of stent thrombosis with shorter-duration 
DAPT . A shorter duration of DAPT results in fewer bleed-
ing complications .30,34–36 Shorter-duration DAPT may be 
most reasonable in patients currently being treated with 
Table 2. Critical (PICoTS-Formatted) Questions on 
DAPT Duration
Q1:  In patients treated with newer (non-first) generation DES for 
(1) SIHD or (2) ACS, compared with 12 months of DAPT, is 3–6 
months of DAPT as effective in preventing stent thrombosis, 
preventing MACE and/or reducing bleeding complications? 
Q2:  In patients treated with newer (non-first) generation DES, 
compared with 12 months of DAPT, does >12 (18–48) months 
of DAPT result in differences in mortality rate, decreased MACE, 
decreased stent thrombosis, and/or increased bleeding?
Q3:  In post-MI (NSTEMI or STEMI) patients who are clinically stable and 
>12 months past their event, does continued DAPT, compared with 
aspirin monotherapy, result in differences in mortality rate, decreased 
nonfatal MI, decreased MACE, and/or increased bleeding?
ACS indicates acute coronary syndrome; DAPT, dual antiplatelet therapy; 
DES, drug-eluting stents; MACE, major adverse cardiac events; MI, myocardial 
infarction; NSTEMI, non–ST-elevation myocardial infarction; PICOTS, 
population, intervention, comparison, outcome, timing, and setting; SIHD, 
stable ischemic heart disease; and STEMI, ST-elevation myocardial infarction.
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“newer-generation” (eg, everolimus- or zotarolimus-elut-
ing) DES, which are associated with lower stent throm-
bosis and MI rates than those of “first-generation” (eg, 
sirolimus- and paclitaxel-eluting) DES, which are rarely, if 
ever, used in current clinical practice .16,36,38
2.3. Studies of Longer-Duration DAPT  
After Stent Implantation
Six RCTs, consisting predominantly of patients treated 
with elective DES implantation, compared prolonged 
DAPT (total therapy duration: 18 to 48 months) with 6 to 
12 months of DAPT to determine whether extended ther-
apy reduces late and very late stent thrombosis and pre-
vents ischemic events associated with disease progres-
sion and plaque rupture at other nonstented sites16,22–27 
(Data Supplement 2) . In the Dual Antiplatelet Therapy 
study—the largest of these trials—patients who had un-
dergone DES implantation, had been treated with DAPT 
for 12 months, and were without ischemic or bleeding 
events during this period were randomized to an addi-
tional 18 months of DAPT or to aspirin monotherapy .16 
Extended DAPT resulted in a 0 .7% absolute reduction in 
very late stent thrombosis, a 2 .0% absolute reduction in 
MI, a 1 .6% absolute reduction in major adverse cardiac 
events (MACE), and a 0 .9% absolute increase in mod-
erate or severe bleeding . In the subgroup of patients 
treated with everolimus-eluting stents—currently the 
most commonly used stent—extended DAPT resulted in 
a 0 .4% absolute reduction in stent thrombosis, a 1 .1% 
absolute reduction in MI, and a 1 .2% absolute increase 
in moderate/severe bleeding .39
Taken as a whole, studies of longer-duration (“pro-
longed” or “extended”) DAPT16,22–27 for an additional 18 
to 36 months after DES found an absolute decrease in 
late stent thrombosis and ischemic complications of 
≈1% to 2% and an absolute increase in bleeding compli-
cations of ≈1% (Data Supplements 2 and 3) . A weighted 
risk-benefit analysis by the ERC of studies of patients 
treated with DES found 6 fewer MIs and 3 fewer stent 
thromboses but 5 additional major bleeds per 1000 pa-
tients treated with prolonged DAPT per year .30
2.4. other Studies Relevant to DAPT >1 year  
After MI
The CHARISMA (Clopidogrel for High Atherothrombotic 
Risk and Ischemic Stabilization, Management, and Avoid-
ance) trial randomized patients with established athero-
sclerosis or at high risk of clinical atherosclerotic disease 
to either DAPT (with clopidogrel) or aspirin monotherapy; 
with DAPT, no significant reduction was found in ischemic 
effects at a median follow-up of 28 months, but there was 
a 0 .4% absolute increase in severe bleeding .40 A post hoc 
analysis of patients enrolled in the study with prior MI found 
a 1 .7% absolute decrease in the composite endpoint of 
cardiovascular death, MI, or stroke events with DAPT, with 
no benefit in those with CAD without prior MI .40,41
Patients in the PEGASUS-TIMI 54 (Prevention of Car-
diovascular Events in Patients with Prior Heart Attack 
Using Ticagrelor Compared to Placebo on a Background 
of Aspirin—Thrombolysis In Myocardial Infarction 54) 
trial were randomized 1 to 3 years after MI with addi-
tional high-risk features to either DAPT (with ticagrelor 
60 mg or 90 mg twice daily) or continued aspirin mono-
therapy .28 After a mean of 33 months of therapy, DAPT, 
when compared with aspirin monotherapy, resulted in a 
1 .2% to 1 .3% absolute reduction in the primary compos-
ite endpoint of cardiovascular death, MI, or stroke and a 
1 .2% to 1 .5% absolute increase in major bleeding, with 
no excess in fatal bleeding or intracranial hemorrhage . 
In subgroup analysis, the greatest reduction in ischemic 
events with prolonged DAPT was in patients in whom 
P2Y12 inhibitor therapy either had not been discontinued 
or had been discontinued for ≤30 days (absolute reduc-
tion in MACE: 1 .9% to 2 .5%) . No benefit was seen in 
patients in whom P2Y12 inhibitor therapy had been dis-
continued >1 year before enrollment in the study .42
In the Dual Antiplatelet Therapy study, the benefit/risk 
ratio for prolonged DAPT was more favorable for those 
presenting with MI than those with SIHD .43 In an analysis 
of patients with a history of prior MI enrolled in 6 RCTs of 
extended/prolonged DAPT, extended DAPT significantly de-
creased the absolute risk of MACE by 1 .1% and significantly 
increased the absolute risk of major bleeding by 0 .8% .44
Taken as a whole, trials of prolonged or extended DAPT 
suggest that the benefit/risk ratio of prolonged DAPT may 
be more favorable for those with prior MI, with an absolute 
decrease in ischemic events of ≈1% to 3% at the cost 
of an absolute increase in bleeding events of ≈1% over 
the course of several years of prolonged or extended 
therapy (median durations of therapy: 18 to 33 months) 
(Data Supplements 3 and 4) . This appears biologically 
plausible because patients with prior MI (usually mediated 
by plaque rupture) may be at greater risk for future plaque 
rupture than those without prior MI .37,40,41
2.5. Prolonged/Extended DAPT and  
Mortality Rate
An unexpected finding in the Dual Antiplatelet Therapy 
study16 was a borderline-significant increase in overall 
mortality rate (0 .5% absolute increase) with 30 months 
of DAPT versus 12 months of DAPT in DES-treated pa-
tients, which was due to significantly increased deaths 
from noncardiovascular causes (most commonly cancer), 
with no increase in cardiovascular deaths, and no signifi-
cant increase in fatal bleeding .45 Five subsequent meta-
analyses35–37,46,47 restricted to RCTs of studies enrolling 
patients treated with predominantly newer generation 
DES, published prior to the presentation of the OPTIDUAL 
(Optimal Dual Antiplatelet Therapy) trial, found numerical-
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ly36,47 or statistically35,37,46 significant increased risk of all-
cause (though not cardiovascular) death associated with 
prolonged duration of DAPT (Data Supplements 3 and 4) .
In contrast, a meta-analysis that combined studies of 
DAPT duration after stent implantation with studies of 
DAPT duration for other indications48 and an analysis of 
6 trials restricted to post-MI patients treated with DAPT44 
found no increase in cardiovascular or noncardiovascular 
mortality rate associated with prolonged DAPT (Data Sup-
plement 3) . A US Food and Drug Administration drug safe-
ty communication, based on an evaluation of long-term 
clinical trials of patients with cardiovascular disease or 
stroke treated with clopidogrel, concluded that long-term 
clopidogrel treatment did not increase the risk of all-cause 
death or cancer-related death .49 The primary analysis by 
the ERC of 11 RCTs (including OPTIDUAL) compared use 
of DAPT for 18 to 48 months with use of DAPT for 6 to 
12 months in patients who had received predominantly 
newer-generation DES and found no statistically signifi-
cant difference in all-cause mortality rate .30
A majority of writing group members believe the data 
as a whole do not seem to suggest prolonged DAPT 
results in increased mortality .
3. ovERRIDING CoNCEPTS AND 
RECoMMENDATIoNS FoR DAPT AND 
DURATIoN oF THERAPy
3.1. General overriding Concepts
Overriding concepts and relevant recommendations 
for DAPT and duration of therapy are summarized in 
Table 3 . Intensification of antiplatelet therapy, with the 
addition of a P2Y12 inhibitor to aspirin monotherapy, ne-
cessitates a fundamental tradeoff between decreasing 
ischemic risk and increasing bleeding risk .40,41,50–52 Simi-
larly, longer compared with shorter duration of DAPT 
generally results in decreased ischemic risk at the ex-
pense of increased bleeding risk .16,24,28,30,46 Use of more 
potent P2Y12 inhibitors (ticagrelor or prasugrel) in place 
of clopidogrel also results in decreased ischemic risk 
and increased bleeding risk .53–55
In general, recommendations for duration of DAPT 
in the present focused update consist of a Class I rec-
ommendation (“should be given”) for a minimum period 
of time (in most cases 6 to 12 months) and a Class 
IIb recommendation (“may be considered”) for con-
tinuation of DAPT beyond that period of time . Short-
er-duration DAPT can be considered for patients at 
lower ischemic risk with high bleeding risk, whereas 
longer-duration DAPT may be reasonable for patients at 
higher ischemic risk with lower bleeding risk . These rec-
ommendations do not generally apply to patients treated 
with oral anticoagulant therapy, who were excluded from 
almost all studies of DAPT duration and who are at signif-
icantly increased bleeding risk (as discussed in Section 
3 .4) . Decisions about duration of DAPT are best made 
on an individual basis and should integrate clinical judg-
ment, assessment of the benefit/risk ratio, and patient 
preference . Aspirin therapy is almost always continued 
indefinitely in patients with CAD, and recommendations 
on duration of DAPT should be taken to mean the recom-
mended duration of P2Y12 inhibitor therapy (in addition to 
aspirin therapy) . Figure 1 summarizes recommendations 
for duration of DAPT according to clinical status .
3.2. Factors Associated With Increased Ischemic 
and Bleeding Risk
Factors that have been associated with increased isch-
emic risk (including increased risk of stent thrombosis) 
Table 3. overriding Concepts and Updated 
Recommendations for DAPT and Duration
Intensification of antiplatelet therapy, with the addition of a P2Y
12
 
inhibitor to aspirin monotherapy, as well as prolongation of DAPT, 
necessitates a fundamental tradeoff between decreasing ischemic 
risk and increasing bleeding risk. Decisions about treatment with and 
duration of DAPT require a thoughtful assessment of the benefit/risk 
ratio, integration of study data, and consideration of patient preference.
In general, shorter-duration DAPT can be considered for patients at 
lower ischemic risk with high bleeding risk, whereas longer-duration 
DAPT may be reasonable for patients at higher ischemic risk with lower 
bleeding risk.
Prior recommendations for duration of DAPT for patients treated 
with DES were based on data from “first-generation” DES, which are 
rarely if ever used in current clinical practice. Compared with first-
generation stents, newer-generation stents have an improved safety 
profile and lower risk of stent thrombosis. Recommendations in this 
focused update apply to newer-generation stents.
Updated recommendations for duration of DAPT are now similar for 
patients with NSTE-ACS and STEMI, as both are part of the spectrum 
of acute coronary syndrome.
A Class I recommendation (“should be given”) in most clinical settings 
is made for at least 6–12 months of DAPT (depending on the setting), 
and a Class IIb recommendation (“may be reasonable”) is made for 
prolonged DAPT beyond this initial 6- to 12-month period.
In studies of prolonged DAPT after DES implantation or after MI, duration 
of therapy was limited to several years (akin to many other studied 
therapies). Thus, in patients for whom the benefit/risk ratio seemingly 
favors prolonged therapy, the true optimal duration of therapy is unknown.
Recommendations in the document apply specifically to duration of P2Y
12
 
inhibitor therapy in patients with CAD treated with DAPT. Aspirin therapy 
should almost always be continued indefinitely in patients with CAD.
Lower daily doses of aspirin, including in patients treated with 
DAPT, are associated with lower bleeding complications and 
comparable ischemic protection56–60 than are higher doses of 
aspirin. The recommended daily dose of aspirin in patients treated 
with DAPT is 81 mg (range, 75 mg to 100 mg).
CAD indicates coronary artery disease; DAPT, dual antiplatelet therapy; DES, 
drug-eluting stent; MI, myocardial infarction; NSTE-ACS, non–ST-elevation 
acute coronary syndrome; and STEMI, ST-elevation myocardial infarction.
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and increased bleeding risk are listed in Table 4 . Individu-
al patients may have factors for both increased ischemic 
and bleeding risk, and some factors are associated with 
both increased ischemic and bleeding risk, making it dif-
ficult in many patients to assess the benefit/risk ratio of 
prolonged DAPT .
A new risk score (the “DAPT score”), derived from the 
Dual Antiplatelet Therapy study, may be useful for deci-
sions about whether to continue (prolong or extend) DAPT 
in patients treated with coronary stent implantation . Analy-
sis of study data suggests that in patients treated for 1 
year with DAPT without significant bleeding or ischemic 
events, the benefit/risk ratio with prolonged DAPT may be 
favorable for those with a high DAPT score (≥2) because 
prolonged DAPT reduces net (ischemic plus bleeding) 
events when compared with nonprolonged DAPT .61 Con-
versely, in those with a low DAPT score (<2), the benefit/
risk ratio with prolonged DAPT is not favorable (increased 
bleeding without a reduction in ischemic events) . Factors 
that contribute to a high DAPT score include diabetes mel-
litus, current cigarette use, prior PCI or prior MI, conges-
tive heart failure or left ventricular ejection fraction <30%, 
MI at presentation, vein graft PCI, and stent diameter <3 
mm; older age contributes to a low (less favorable) DAPT 
score . Factors and their weighting used to calculate a 
DAPT score are provided in Table 5 .
Figure 1. Master treatment algorithm for duration of P2y12 inhibitor therapy in patients with CAD treated with DAPT. 
Colors correspond to Class of Recommendation in Table 1 . Clopidogrel is the only currently used P2Y12 inhibitor studied in 
patients with SIHD undergoing PCI . Aspirin therapy is almost always continued indefinitely in patients with CAD . Patients with 
a history of ACS >1 year prior who have since remained free of recurrent ACS are considered to have transitioned to SIHD . 
In patients treated with DAPT after DES implantation who develop a high risk of bleeding (eg, treatment with oral anticoagu-
lant therapy), are at high risk of severe bleeding complication (eg, major intracranial surgery), or develop significant overt 
bleeding, discontinuation of P2Y12 inhibitor therapy after 3 months for SIHD or after 6 months for ACS may be reasonable . 
Arrows at the bottom of the figure denote that the optimal duration of prolonged DAPT is not established . ACS indicates acute 
coronary syndrome; BMS, bare metal stent; CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; 
DAPT, dual antiplatelet therapy; DES, drug-eluting stent; Hx, history; lytic, fibrinolytic therapy; NSTE-ACS, non–ST-elevation 
acute coronary syndrome; PCI, percutaneous coronary intervention; SIHD, stable ischemic heart disease; S/P, status post; 
and STEMI, ST-elevation myocardial infarction .
CAD
SIHD
Acute/Recent ACS 
(NSTE-ACS or STEMI)
No Hx of MI, PCI or 
recent (within 12 mo)
CABG
S/P CABG Medical Therapy Lytic (STEMI) PCI (BMS or DES) CABG
Class III:
 No Benefit
6 mo
12 mo
S/P PCI
BMS DES
No high risk of bleeding and 
no significant overt bleeding on DAPT
0 mo
No high risk of bleeding and
 no significant overt bleeding on DAPT
Class IIb:
>6 mo may be 
reasonable 
Class I:
At least 6 mo 
(clopidogrel)
Class I:
 At least 1 mo 
(clopidogrel)
Class I:
At least 12 mo  
(clopidogrel,
ticagrelor)
Class I:
Minimum 14 d 
and ideally at 
least 12 mos 
(clopidogrel)
Class I:
At least 12 mo 
(clopidogrel,
prasugrel,
ticagrelor)
Class I:
After CABG,
resume P2Y12
inhibitor to 
complete 1 y of 
DAPT 
Class IIb:
>12 mo may be reasonable 
Class IIb:
12 mo may be 
reasonable 
(clopidogrel)
Class IIb:
>1 mo may be 
reasonable 
D
ow
nloaded from
 http://ahajournals.org by on August 13, 2019
Focused Update on Duration of Dual Antiplatelet Therapy
CLINICAL STATEM
ENTS 
AND GUIDELINES
Circulation. 2016;134:e123–e155. DOI: 10.1161/CIR.0000000000000404 September 6, 2016 e131
3.3. Specific P2y12 Inhibitors: Recommendations
See Data Supplement 5 for evidence supporting these 
recommendations .
In the PLATO (Platelet Inhibition and Patient Out-
comes) trial,53 patients with ACS were treated with ei-
ther medical therapy alone or medical therapy plus PCI . 
Treatment with ticagrelor 90 mg twice daily, compared 
with clopidogrel 75 mg once daily, resulted in fewer 
ischemic complications and stent thromboses but more 
frequent non–CABG-related bleeding (Data Supplement 
5) . In the TRITON-TIMI 38 (Therapeutic Outcomes by Op-
timizing Platelet Inhibition With Prasugrel–Thrombolysis 
In Myocardial Infarction 38)54 study, patients with ACS 
undergoing planned PCI were treated with prasugrel 10 
mg daily, compared with clopidogrel 75 mg daily . Pra-
sugrel treatment resulted in fewer ischemic complica-
tions and stent thromboses but more frequent bleeding, 
including life-threatening and fatal bleeding . Because of 
increased rates of major bleeding with prasugrel (com-
pared with clopidogrel), there was no net benefit of pra-
sugrel therapy in those ≥75 years of age and those <60 
kg, and there was net harm (including increased risk of 
intracranial hemorrhage) in those with prior stroke or 
transient ischemic attack (TIA) . The Class IIa preferential 
recommendations for ticagrelor 90 mg twice daily and 
for prasugrel 10 mg once daily (compared with clopi-
dogrel) in the 2014 Non–ST-Elevation Acute Coronary 
Syndromes (NSTE-ACS) guideline are continued in this 
focused update and are now included in relevant PCI and 
ST-Elevation Myocardial Infarction (STEMI) recommenda-
tions, as well .
In the PEGASUS-TIMI 54 study of post-MI patients, 
both 60-mg and 90-mg twice-daily doses of ticagre-
lor were evaluated .28 The benefit/risk ratio appears 
to be numerically more favorable for the 60-mg dose, 
although no formal statistical comparison was made 
between results of the 2 dosing regimens . The 60-mg 
twice-daily dose has now been approved by the US 
Food and Drug Administration for reduction in ischemic 
events in patients with ACS or a history of MI .73
3.4. Platelet Function Testing, Genetic Testing,  
and Switching of P2y12 Inhibitors
The role of platelet function testing and genetic testing 
in patients treated with DAPT is addressed in the 2011 
ACCF/AHA/SCAI PCI guideline and the 2014 ACC/AHA 
NSTE-ACS guideline .9,14 To date, no RCT has demonstrat-
ed that routine platelet function testing or genetic testing 
to guide P2Y12 inhibitor therapy improves outcome; thus, 
the routine use of platelet function and genetic testing is 
not recommended (Class III: No Benefit) .
No randomized data are available on the long-term 
safety or efficacy of “switching” patients treated for 
weeks or months with a P2Y12 inhibitor to a different 
P2Y12 inhibitor .
Table 4. Clinical and Procedural Factors Associated 
With Increased Ischemic Risk (Including Stent 
Thrombosis) or Increased Bleeding Risk62–70
Increased Ischemic Risk/Risk 
of Stent Thrombosis (may 
favor longer-duration DAPT)
Increased Bleeding Risk (may 
favor shorter-duration DAPT)
Increased ischemic risk History of prior bleeding
  Advanced age Oral anticoagulant therapy
  ACS presentation Female sex
  Multiple prior MIs Advanced age
  Extensive CAD Low body weight
  Diabetes mellitus CKD
  CKD Diabetes mellitus
Increased risk of stent 
thrombosis
Anemia
  ACS presentation Chronic steroid or NSAID therapy
  Diabetes mellitus
  Left ventricular ejection  
fraction <40%
  First-generation drug-eluting 
stent
  Stent undersizing
  Stent underdeployment
  Small stent diameter
  Greater stent length
  Bifurcation stents
  In-stent restenosis
ACS indicates acute coronary syndrome; CAD, coronary artery disease; 
CKD, chronic kidney disease; DAPT, dual antiplatelet therapy; MI, myocardial 
infarction; and NSAID, nonsteroidal anti-inflammatory drug.
Recommendations for Specific P2y12 Inhibitors
CoR LoE Recommendations
IIa B-R
In patients with ACS (NSTE-ACS or STEMI) 
treated with DAPT after coronary stent 
implantation and in patients with NSTE-ACS 
treated with medical therapy alone (without 
revascularization), it is reasonable to use 
ticagrelor in preference to clopidogrel for 
maintenance P2Y
12
 inhibitor therapy.53,71,72
IIa B-R
In patients with ACS (NSTE-ACS or STEMI) treated 
with DAPT after coronary stent implantation who 
are not at high risk for bleeding complications and 
who do not have a history of stroke or TIA, it is 
reasonable to choose prasugrel over clopidogrel 
for maintenance P2Y
12
 inhibitor therapy.54,55
III: Harm B-R
Prasugrel should not be administered to patients 
with a prior history of stroke or TIA.54
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3.5. Proton Pump Inhibitors and DAPT
The use of proton pump inhibitors (PPIs) in patients 
treated with DAPT is discussed in a 2010 ACCF/ACG/
AHA expert consensus document .74 Recommendations 
on the use of PPIs are given in the 2011 ACCF/AHA/
SCAI PCI guideline .9 PPIs should be used in patients with 
a history of prior gastrointestinal bleeding treated with 
DAPT (Class I) . In patients with increased risk of gastro-
intestinal bleeding, including those with advanced age 
and those with concomitant use of warfarin, steroids, 
or nonsteroidal anti-inflammatory drugs, use of PPIs is 
reasonable (Class IIa) . Routine use of PPIs is not recom-
mended for patients at low risk of gastrointestinal bleed-
ing (Class III: No Benefit) .
3.6. Aspirin Dosing in Patients Treated With  
DAPT: Recommendation
See Data Supplement 6 for evidence supporting this rec-
ommendation .
Because aspirin dosing recommendations across 
ACC/AHA clinical practice guidelines are not consistent 
with regard to dose or class of recommendation, and 
because aspirin is a component of DAPT, a compre-
hensive review of these issues was undertaken . Large 
overviews, including studies of nearly 200 000 per-
sons, have consistently shown that lower aspirin doses 
(≤100 mg daily) are associated with less major and total 
bleeding than are higher doses, either when used as 
monotherapy or when combined with the P2Y12 inhibitor 
clopidogrel .56,58,75,76,78 Daily aspirin doses as low as 30 
mg to 50 mg inactivate the platelet cyclo-oxygenase-1 
enzyme and inhibit thromboxane production .79–81 Stud-
ies comparing lower (75 mg to 150 mg) with higher 
aspirin doses have consistently found comparable 
ischemic event rates with either dose when used as 
monotherapy or when combined with the P2Y12 inhibitor 
clopidogrel .56–60,78 The efficacy of ticagrelor seems to 
be decreased in patients treated with higher aspirin dos-
es (≥300 mg daily) versus lower aspirin doses (≤100 
mg daily) .82 On the basis of available data, the optimal 
range of aspirin dose in patients treated with DAPT that 
provides maximal protection from ischemic events and 
minimizes bleeding risk appears to be 75 mg to 100 mg 
(Data Supplement 6) . For practical purposes, because 
the relevant aspirin dose available in the United States 
is 81 mg, this maintenance dose is recommended in pa-
tients with CAD treated with DAPT . The ongoing ADAPT-
ABLE (Aspirin Dosing: A Patient-Centric Trial Assessing 
Benefits and Long-term Effective ness) trial, which the 
present writing group endorses, is expected to yield ad-
ditional information on optimal aspirin dosing in patients 
with atherosclerotic cardiovascular disease .83
3.7. Triple Therapy (Aspirin, P2y12 Inhibitor,  
and oral Anticoagulant)
The recommended management of patients on “triple 
therapy” (aspirin, P2Y12 inhibitor, and oral anticoagulant) 
is beyond the scope of this focused update . However, a 
brief discussion of the topic is included for the purposes 
of completeness and end-user education .
Compared with oral anticoagulation therapy alone, 
the addition of DAPT to oral anticoagulant therapy re-
sults in at least a 2- to 3-fold increase in bleeding compli-
cations .84–87 Discussion and recommendations on triple 
therapy are provided in the 2014 ACC/AHA NSTE-ACS 
guideline,14 a 2014 European joint consensus docu-
ment,88 a North American consensus document,85 and 
several comprehensive state-of-the-art papers and re-
views . A partial summary and synthesis of these recom-
mendations are given in Table 6 .
One trial comparing “double therapy” (oral anticoagu-
lant plus clopidogrel) with triple therapy (oral anticoagu-
lant plus aspirin and clopidogrel)89 and 1 trial comparing 
differing durations of triple therapy have been pub-
lished .90 Several more similar trials comparing oral anti-
coagulant therapy plus P2Y12 inhibitor with triple therapy 
are ongoing .
Recommendation for Aspirin Dosing in Patients 
Treated With DAPT
CoR LoE Recommendation
I B-NR
In patients treated with DAPT, a daily aspirin 
dose of 81 mg (range, 75 mg to 100 mg) is 
recommended.56–60,75–78
Table 5. Factors Used to Calculate a “DAPT Score”
variable Points
Age ≥75 y -2
Age 65 to <75 y -1
Age <65 y 0
Current cigarette smoker 1
Diabetes mellitus 1
MI at presentation 1
Prior PCI or prior MI 1
Stent diameter <3 mm 1
Paclitaxel-eluting stent 1
CHF or LVEF <30% 2
Saphenous vein graft PCI 2
A score of ≥2 is associated with a favorable benefit/risk ratio for 
prolonged DAPT while a score of <2 is associated with an unfavorable 
benefit/risk ratio.
CHF indicates congestive heart failure; DAPT, dual antiplatelet therapy; 
LVEF, left ventricular ejection fraction; MI, myocardial infarction; and PCI, 
percutaneous coronary intervention.
Adapted with permission from Yeh et al.61
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4. PERCUTANEoUS CoRoNARy INTERvENTIoN
4.1. Duration of DAPT in Patients With SIHD 
Treated With PCI: Recommendations
See Data Supplements 1 to 3 and 6 to 9 for evidence 
supporting these recommendations .
4.2. Duration of DAPT in Patients With ACS Treated  
With PCI: Recommendations
See Data Supplements 1 to 9 for evidence supporting 
these recommendations .
Table 6. Summary and Synthesis of Guideline, 
Expert Consensus Documents, and Comprehensive 
Review Article Recommendations on the 
Management of Patients Treated With Triple 
Therapy14,88,91–93
Assess ischemic and bleeding risks using validated risk predictors  
(eg, CHA
2
DS
2
-VASc, HAS-BLED)
Keep triple therapy duration as short as possible; dual therapy  
only (oral anticoagulant and clopidogrel) may be considered in  
select patients
Consider a target INR of 2.0–2.5 when warfarin is used
Clopidogrel is the P2Y
12
 inhibitor of choice
Use low-dose (≤100 mg daily) aspirin
PPIs should be used in patients with a history of gastrointestinal 
bleeding and are reasonable to use in patients with increased risk of 
gastrointestinal bleeding
CHA
2
DS
2
-VASc indicates congestive heart failure, hypertension, age ≥75 
years (doubled), diabetes mellitus, prior stroke or transient ischemic attack or 
thromboembolism (doubled), vascular disease, age 65–74 years, sex category; 
HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding 
history or predisposition, labile INR, elderly, drugs/alcohol concomitantly; INR, 
international normalized ratio; and PPIs, proton pump inhibitors.
Recommendations for Duration of DAPT in Patients 
With SIHD Treated With PCI
CoR LoE Recommendations
I A
In patients with SIHD treated with DAPT after  
BMS implantation, P2Y
12
 inhibitor therapy 
(clopidogrel) should be given for a minimum  
of 1 month.94,95
I B-R SR
In patients with SIHD treated with DAPT  
after DES implantation, P2Y
12
 inhibitor  
therapy (clopidogrel) should be given for at  
least 6 months.17,18,21,30,96,97
I B-NR
In patients treated with DAPT, a daily aspirin 
dose of 81 mg (range, 75 mg to 100 mg) is 
recommended.56–60,75–78
IIb A SR
In patients with SIHD treated with DAPT after BMS 
or DES implantation who have tolerated DAPT 
without a bleeding complication and who are not 
at high bleeding risk (eg, prior bleeding on DAPT, 
coagulopathy, oral anticoagulant use), continuation 
of DAPT with clopidogrel for longer than 1 month 
in patients treated with BMS or longer than 6 
months in patients treated with DES may be 
reasonable.16,22,24–26,30,50
IIb C-LD
In patients with SIHD treated with DAPT after DES 
implantation who develop a high risk of bleeding (eg, 
treatment with oral anticoagulant therapy), are at 
high risk of severe bleeding complication (eg, major 
intracranial surgery), or develop significant overt 
bleeding, discontinuation of P2Y
12
 inhibitor therapy 
after 3 months may be reasonable.19,20,34,36,37
SR indicates systematic review.
Recommendations for Duration of DAPT in Patients 
With SIHD Treated With PCI (Continued)
CoR LoE Recommendations
Recommendations for Duration of DAPT in Patients 
With ACS Treated With PCI
CoR LoE Recommendations
I B-R
In patients with ACS (NSTE-ACS or STEMI) treated  
with DAPT after BMS or DES implantation, P2Y
12
 
inhibitor therapy (clopidogrel, prasugrel, or ticagrelor) 
should be given for at least 12 months.16,50–55,72,96–98
I B-NR
In patients treated with DAPT, a daily aspirin 
dose of 81 mg (range, 75 mg to 100 mg) is 
recommended.56–60,75–78
IIa B-R
In patients with ACS (NSTE-ACS or STEMI) treated with 
DAPT after coronary stent implantation, it is reasonable 
to use ticagrelor in preference to clopidogrel for 
maintenance P2Y
12
 inhibitor therapy.53,72
IIa B-R
In patients with ACS (NSTE-ACS or STEMI) treated 
with DAPT after coronary stent implantation who 
are not at high risk for bleeding complications and 
who do not have a history of stroke or TIA, it is 
reasonable to choose prasugrel over clopidogrel for 
maintenance P2Y
12
 inhibitor therapy.54,55
IIb A SR
In patients with ACS (NSTE-ACS or STEMI) treated 
with coronary stent implantation who have 
tolerated DAPT without a bleeding complication 
and who are not at high bleeding risk (eg, prior 
bleeding on DAPT, coagulopathy, oral anticoagulant 
use), continuation of DAPT (clopidogrel, prasugrel, 
or ticagrelor) for longer than 12 months may be 
reasonable.16,22–26,28,30,40,41,43,53,54,72
IIb C-LD
In patients with ACS treated with DAPT after DES 
implantation who develop a high risk of bleeding 
(eg, treatment with oral anticoagulant therapy), are at 
high risk of severe bleeding complication (eg, major 
intracranial surgery), or develop significant overt 
bleeding, discontinuation of P2Y
12
 inhibitor therapy 
after 6 months may be reasonable.17–21,34,36,37
III:  
Harm
B-R
Prasugrel should not be administered to patients 
with a prior history of stroke or TIA.54
SR indicates systematic review.
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4.3. Duration of DAPT in Patients With SIHD and 
ACS Treated with PCI
DAPT in patients treated with coronary stent implanta-
tion reduces the risk of stent thrombosis and ischemic 
events50,51,94,95,99 (Data Supplement 7) . The risk of stent 
thrombosis in patients treated with a bare metal stent 
(BMS) is greatest in the first days to weeks after implan-
tation .99,100 Cessation of DAPT during this period, par-
ticularly in cases of patients undergoing surgery, is as-
sociated with an unacceptable rate of often catastrophic 
stent thrombosis .101–103 Thus, a minimum duration of 
DAPT of 1 month is generally recommended for patients 
treated with BMS . In current practice, BMS are generally 
reserved for patients who cannot receive DAPT for more 
than ≈1 month for reasons of active bleeding, nonadher-
ence to medical therapy, or planned surgery .
The recommended minimum duration of DAPT in pa-
tients treated with first-generation DES, based primarily on 
observational data and one subgroup analysis, has been 
12 months .9,51,97,104,105 Compared with first-generation DES, 
currently used newer-generation DES have a lower risk of 
stent thrombosis and appear to require a shorter minimum 
duration of DAPT .17,18,21,38,96,97 Five RCTs17–21 of primarily 
low-risk (non-ACS) patients treated with DES comparing 
shorter-duration (3 to 6 months) DAPT with 12 months of 
DAPT, as well as several meta-analyses34–37 and an analysis 
by the ERC,30 did not find an increased risk of stent throm-
bosis with shorter-duration DAPT, although the individual tri-
als were underpowered to detect such a difference (Data 
Supplements 1 and 3) . Therefore, in patients with SIHD 
treated with DES, the minimum recommended duration of 
DAPT has been decreased from 12 to 6 months .
The PCI-CURE analysis51 of patients in the CURE (Clopi-
dogrel in Unstable Angina to Prevent Recurrent Events) 
trial52 demonstrated that treatment with DAPT for up to 
12 months in patients with NSTE-ACS treated with BMS re-
duced ischemic events compared with aspirin monotherapy 
(Data Supplement 4) . Based primarily on the CURE trial and 
PCI-CURE analyses, the prior recommendation that patients 
with NSTE-ACS treated with coronary stent implantation be 
treated with DAPT for at least 12 months is continued in this 
update and has been extrapolated to patients with STEMI 
treated with PCI as well, on the basis of the consideration 
that NSTE-ACS and STEMI are part of the spectrum of ACS .
As detailed in Section 2, treatment with prolonged (or 
“extended”) DAPT beyond a minimum recommended dura-
tion of therapy necessitates a fundamental tradeoff between 
decreasing ischemic risk (eg, MI and stent thrombosis) and 
increasing bleeding risk .16,30,34,36,37,46 Prolonged or extended 
DAPT for an additional 18 to 36 months (after an initial 6 to 
12 months of DAPT) in patients treated with DES implanta-
tion results in an absolute decrease in stent thrombosis and 
ischemic complications of ≈1% to 2% and an absolute in-
crease in bleeding complications of ≈1% (Data Supplements 
1, 2, and 3) .16,22–27,30,35–37,46 Newer-generation stents, par-
ticularly everolimus-eluting stents, are associated with lower 
rates of stent thrombosis, and the absolute reduction in the 
rate of stent thrombosis with prolonged DAPT in patients 
treated with everolimus-eluting stents is modest .39,106–109
The benefit/risk ratio of prolonged DAPT in patients 
treated with PCI may be more favorable for those with 
prior MI (or ACS) than for those with SIHD .28,41,43 Pre-
liminary data suggest that in patients with a high DAPT 
score the benefit/risk ratio with prolonged DAPT may be 
favorable and that in those with a low DAPT score the 
benefit/risk ratio with prolonged DAPT is not favorable .61 
In patients treated with coronary stent implantation who 
have increased bleeding risk (eg, oral anticoagulation), 
increased risk of severe bleeding complications (eg, ma-
jor intracranial surgery), or significant overt bleeding, the 
benefit/risk ratio may favor shorter-than-recommended 
duration of DAPT .17–21,34,36 Decisions about treatment with 
and duration of DAPT require a thoughtful assessment 
of the benefit/risk ratio, integration of current and future 
study data, and consideration of patient preference .
In studies of drug-eluting bioabsorbable polymer 
stents and bioabsorbable stents (third- and fourth-gener-
ation stents), by study protocol, DAPT was continued for 
at least 6 to 12 months .110–116 In a study of a novel poly-
mer-free and carrier-free drug-coated stent in patients at 
high risk of bleeding complications, by study protocol, 
DAPT was continued for only 1 month .117 These stents 
have not been included in the studies of shorter- or 
longer-duration (prolonged/extended) DAPT discussed 
in this focused update . Because none of these stents 
(except one biodegradable polymer DES) was approved 
by the US Food and Drug Administration at the time this 
focused update was written, recommendations for dura-
tion of DAPT for such stents are not included .
Recommendations for duration of DAPT in patients 
treated with PCI are summarized in Figure 2 .
5. RECoMMENDATIoNS FoR DURATIoN oF 
DAPT IN PATIENTS UNDERGoING CABG
See Data Supplements 4, 6, 10, and 11 for evidence 
supporting these recommendations .
Recommendations for Duration of DAPT in Patients 
Undergoing CABG
CoR LoE Recommendations
I C-Eo
In patients treated with DAPT after coronary 
stent implantation who subsequently undergo 
CABG, P2Y
12
 inhibitor therapy should be resumed 
postoperatively so that DAPT continues until the 
recommended duration of therapy is completed.
I C-LD
In patients with ACS (NSTE-ACS or STEMI) being 
treated with DAPT who undergo CABG, P2Y
12
 inhibitor 
therapy should be resumed after CABG to complete 
12 months of DAPT therapy after ACS.52–54,118–120
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Aspirin therapy after CABG improves vein graft patency, 
particularly during the first postoperative year, and reduces 
MACE .126–130 In the CURE study,52 the reduction in ischemic 
events in patients treated with aspirin plus clopidogrel who 
underwent CABG was consistent with the study population 
as a whole, although benefit was primarily observed mainly 
before the procedure .118 A propensity score analysis of a 
Danish administrative database120 demonstrated during 
a mean follow-up of 466±144 days significantly fewer 
deaths in patients treated with aspirin plus clopidogrel 
than in those treated with aspirin alone, although there 
was no reduction in the incidence of recurrent MI .
The impact of clopidogrel on graft occlusion after 
on-pump CABG has been evaluated in 5 studies (Data 
Supplement 10) . Several randomized and nonrandom-
ized trials and a post hoc substudy analysis of patients 
predominantly undergoing on-pump CABG did not dem-
onstrate any differences in graft patency between anti-
platelet monotherapy and DAPT when assessed at fol-
low-up ranging from 1 month to 1 year after CABG .131–134 
In the only RCT to demonstrate a benefit of DAPT, vein 
graft patency 3 months after CABG was significantly 
higher in patients treated with clopidogrel and aspirin 
(100 mg) than in those receiving aspirin monotherapy .121
Two meta-analyses and 1 systematic overview as-
sessed the potential benefits of DAPT after CABG and 
reported mixed results122,123,135 (Data Supplement 10) . In 
the largest meta-analysis of patients pooled from 5 RCTs 
and 6 observational studies,122 DAPT was associated 
with reduced vein graft occlusion and 30-day mortality 
rate as compared with aspirin monotherapy . A meta-
analysis of only the 5 RCTs123 showed that DAPT was 
associated with a significantly lower vein graft occlusion 
at 1 year versus antiplatelet monotherapy but with no im-
provement in arterial graft patency . Major bleeding after 
surgery was more frequent with DAPT .122,123,135
The benefits of DAPT in off-pump CABG patients 
were noted in terms of improved graft patency124,125 and 
clinical outcome136 in single-center observational stud-
ies124,136 and an RCT125 (Data Supplement 10) .
Only data from post hoc analyses are available on the 
utility of newer P2Y12 inhibitors in patients with ACS who un-
dergo CABG . In a retrospective analysis of patients in the 
TRITON-TIMI 38 study54 who underwent CABG,137 prasugrel 
treatment was associated with a significantly lower 30-day 
mortality rate than that of clopidogrel and more postopera-
tive blood loss . A post hoc analysis of patients who under-
went CABG in the PLATO study53 showed that the primary 
endpoint at 1 year was similar for both treatments, but a 
significant reduction in cardiovascular mortality was noted 
with ticagrelor compared with clopidogrel .138,139
Issues related to the timing of discontinuation of DAPT 
before CABG are beyond the scope of this update but are 
addressed in the 2011 CABG guideline .10 Figure 3 summa-
rizes recommendations for the management and duration 
of P2Y12 inhibitor therapy in patients undergoing CABG .
6. RECoMMENDATIoNS FoR DURATIoN oF 
DAPT IN PATIENTS WITH SIHD
See Data Supplements 1 to 4 and 6 to 11 for evidence 
supporting these recommendations .
I B-NR
In patients treated with DAPT, a daily aspirin 
dose of 81 mg (range, 75 mg to 100 mg) is 
recommended.56–60,75–78
IIb B-NR
In patients with SIHD, DAPT (with clopidogrel 
initiated early postoperatively) for 12 months after 
CABG may be reasonable to improve vein graft 
patency.121–125
Recommendations for Duration of DAPT in Patients 
Undergoing CABG (Continued)
CoR LoE Recommendations
Recommendations for Duration of DAPT in Patients 
With SIHD
CoR LoE Recommendations
I A
In patients with SIHD treated with DAPT after BMS 
implantation, P2Y
12
 inhibitor therapy (clopidogrel) 
should be given for a minimum of 1 month.94,95
I B-R SR
In patients with SIHD treated with DAPT after DES 
implantation, P2Y
12
 inhibitor therapy (clopidogrel) 
should be given for at least 6 months.17,18,21,30,96,97
I B-NR
In patients treated with DAPT, a daily aspirin 
dose of 81 mg (range, 75 mg to 100 mg) is 
recommended.56–60,75–78
IIb A SR
In patients with SIHD being treated with DAPT 
for an MI that occurred 1 to 3 years earlier 
who have tolerated DAPT without a bleeding 
complication and who are not at high bleeding 
risk (eg, prior bleeding on DAPT, coagulopathy, 
oral anticoagulant use), further continuation of 
DAPT may be reasonable.28,30,40,41,44
IIb A SR
In patients with SIHD treated with BMS or 
DES implantation who have tolerated DAPT 
without a bleeding complication and who are 
not at high bleeding risk (eg, prior bleeding on 
DAPT, coagulopathy, oral anticoagulant use), 
continuation of DAPT with clopidogrel for longer 
than 1 month in patients treated with BMS or 
longer than 6 months in patients treated with 
DES may be reasonable.16,22,24–26,30,50
IIb C-LD
In patients with SIHD treated with DAPT after 
DES implantation who develop a high risk of 
bleeding (eg, treatment with oral anticoagulant 
therapy), are at high risk of severe bleeding 
complication (eg, major intracranial surgery), 
or develop significant overt bleeding, 
discontinuation of P2Y
12
 inhibitor therapy after 3 
months may be reasonable.19,20,34,36,37
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For the purposes of this update, patients with a his-
tory of ACS >1 year prior who have remained free of re-
current ACS are considered to have transitioned to SIHD .
In the CHARISMA trial, which randomized patients with 
established atherosclerosis or at high risk of clinical ath-
erosclerotic disease to either DAPT (with clopidogrel) or 
aspirin monotherapy, no significant reduction was found in 
ischemic effects at a median follow-up of 28 months with 
DAPT, but a 0 .4% absolute increase was seen in severe 
bleeding .40 In a post hoc analysis of patients enrolled in 
the study with prior MI, a 1 .7% absolute decrease in the 
composite endpoint of cardiovascular death, MI, or stroke 
events was observed with DAPT, but no benefit was seen in 
Figure 2. Treatment algorithm for duration of P2y12 inhibitor therapy in patients treated with PCI.  
Colors correspond to Class of Recommendation in Table 1 . Arrows at the bottom of the figure denote that the optimal duration of 
prolonged DAPT is not established . Clopidogrel is the only currently used P2Y12 inhibitor studied in patients with SIHD undergoing 
PCI . Aspirin therapy is almost always continued indefinitely in patients with coronary artery disease . *High bleeding risk denotes 
those who have or develop a high risk of bleeding (eg, treatment with oral anticoagulant therapy) or are at increased risk of severe 
bleeding complication (eg, major intracranial surgery) . ACS indicates acute coronary syndrome; BMS, bare metal stent; DAPT, dual 
antiplatelet therapy; DES, drug-eluting stent; PCI, percutaneous coronary intervention; and SIHD, stable ischemic heart disease .
IIb B-NR
In patients with SIHD, treatment with DAPT (with 
clopidogrel initiated early postoperatively) for 
12 months after CABG may be reasonable to 
improve vein graft patency.121–125
III: No 
Benefit
B-R
In patients with SIHD without prior history of 
ACS, coronary stent implantation, or recent 
(within 12 months) CABG, treatment with DAPT 
is not beneficial.28,40–42
SR indicates systematic review.
Recommendations for Duration of DAPT in Patients 
With SIHD (Continued)
CoR LoE Recommendations
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those with CAD without prior MI (Data Supplement 4) .40,41 
In the PEGASUS-TIMI 54 trial, in which stable patients 1 
to 3 years after MI with additional high-risk features were 
randomized to either DAPT (with ticagrelor 60 mg or 90 
mg twice daily) or continued aspirin monotherapy, a mean 
of 33 months of DAPT led to a 1 .2% to 1 .3% absolute 
reduction in ischemic events and a 1 .2% to 1 .5% increase 
in major bleeding .28 In subgroup analysis, the greatest re-
duction in ischemic events was in patients in whom P2Y12 
inhibitor therapy either had not been discontinued or had 
been discontinued ≤30 days before enrollment in the 
study (absolute reduction in MACE: 1 .9% to 2 .5%), and 
no benefit was seen in patients in whom P2Y12 inhibitor 
therapy had been discontinued >1 year before enrollment 
in the study .42 On the basis of all studies of DAPT in post-
MI patients, extended DAPT for approximately 18 to 36 
months leads to an absolute decrease in ischemic compli-
cations of ≈1% to 3% and an absolute increase in bleeding 
complications of ≈1% (Data Supplement 4) .28,40,41,43,44
DAPT is not recommended in patients with SIHD with-
out prior stent implantation and no history of ACS or MI . 
Decisions about treatment with and duration of DAPT in 
patients with SIHD with a history of MI or coronary stent 
implantation require a thoughtful assessment of the ben-
efit/risk ratio, integration of study data, and consider-
ation of patient preference .
Figure 4 summarizes recommendations on duration 
of P2Y12 inhibitor therapy in patients with SIHD .
7. ACUTE CoRoNARy SyNDRoME  
(NSTE-ACS AND STEMI)
7.1. Duration of DAPT in Patients With ACS 
Treated With Medical Therapy Alone (Without 
Revascularization or Fibrinolytic Therapy): 
Recommendations
See Data Supplements 4 to 6 for evidence supporting 
these recommendations .
Recommendations for Duration of DAPT in Patients 
With ACS Treated with Medical Therapy Alone
CoR LoE Recommendations
I B-R
In patients with ACS who are managed with 
medical therapy alone (without revascularization or 
fibrinolytic therapy) and treated with DAPT, P2Y
12
 
inhibitor therapy (clopidogrel or ticagrelor) should 
be continued for at least 12 months.52,71,140,141
I B-NR
In patients treated with DAPT, a daily aspirin 
dose of 81 mg (range, 75 mg to 100 mg) is 
recommended.56–60,75–78
IIa B-R
In patients with NSTE–ACS who are managed with 
medical therapy alone (without revascularization 
or fibrinolytic therapy) and treated with DAPT, it 
is reasonable to use ticagrelor in preference to 
clopidogrel for maintenance P2Y
12
 inhibitor therapy.53,71
Figure 3. Treatment algorithm for management and duration of P2y12 inhibitor therapy in patients undergoing CABG.  
Colors correspond to Class of Recommendation in Table 1 . Aspirin therapy is almost always continued indefinitely in patients with 
coronary artery disease . *Duration of DAPT therapy can vary from as little as 4 weeks to >12 months, depending on the clinical 
setting and bleeding risk . ACS indicates acute coronary syndrome; CABG, coronary artery bypass graft surgery; DAPT, dual 
antiplatelet therapy; NSTE-ACS, non–ST-elevation acute coronary syndromes; PCI, percutaneous coronary intervention; post-op, 
postoperatively; SIHD, stable ischemic heart disease; and S/P, status post .
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7.2. Duration of DAPT in Patients With STEMI Treated 
With Fibrinolytic Therapy: Recommendations
See Data Supplements 4 and 6 for evidence supporting 
these recommendations .
7.3. Duration of DAPT in Patients With ACS 
Treated With PCI: Recommendations
See Data Supplements 1 to 9 for evidence supporting 
these recommendations .
7.4. Duration of DAPT in Patients With ACS 
Treated With CABG: Recommendation
See Data Supplement 4 and 11 for evidence supporting 
this recommendation .
7.5. Duration of DAPT in Patients With ACS
Aspirin remains the cornerstone of antiplatelet ther-
apy in patients with ACS . Further platelet inhibition, 
IIb A SR
In patients with ACS treated with medical therapy 
alone (without revascularization or fibrinolytic 
therapy) who have tolerated DAPT without bleeding 
complication and who are not at high bleeding risk 
(eg, prior bleeding on DAPT, coagulopathy, oral 
anticoagulant use), continuation of DAPT for longer 
than 12 months may be reasonable.28,30,40,41,43,53,71,141
SR indicates systematic review.
Recommendations for Duration of DAPT in Patients 
With ACS Treated with Medical Therapy Alone 
(Continued)
CoR LoE Recommendations
Recommendations for Duration of DAPT in Patients 
With STEMI Treated With Fibrinolytic Therapy
CoR LoE Recommendations
I
A
In patients with STEMI treated with DAPT in 
conjunction with fibrinolytic therapy, P2Y
12
 inhibitor 
therapy (clopidogrel) should be continued for a 
minimum of 14 days (Level of Evidence: A)140,142 and 
ideally at least 12 months (Level of Evidence: C-EO). 
C-EO
I B-NR
In patients treated with DAPT, a daily aspirin 
dose of 81 mg (range, 75 mg to 100 mg) is 
recommended.56–60,75–78
IIb A SR
In patients with STEMI treated with fibrinolytic 
therapy who have tolerated DAPT without 
bleeding complication and who are not at 
high bleeding risk (eg, prior bleeding on DAPT, 
coagulopathy, oral anticoagulant use), continuation 
of DAPT for longer than 12 months may be 
reasonable.16,22–26,28,30,40,41,43,53,54,71,72,141
SR indicates systematic review.
Recommendations for Duration of DAPT in Patients 
With ACS Treated With PCI
CoR LoE Recommendations
I B-R
In patients with ACS treated with DAPT after 
BMS or DES implantation, P2Y
12
 inhibitor therapy 
(clopidogrel, prasugrel, or ticagrelor) should be 
given for at least 12 months.16,50–55,72,96–98
I B-NR
In patients treated with DAPT, a daily aspirin 
dose of 81 mg (range, 75 mg to 100 mg) is 
recommended.56–60,75–78
IIa B-R
In patients with ACS treated with DAPT  
after coronary stent implantation, it is 
reasonable to use ticagrelor in preference to 
clopidogrel for maintenance P2Y
12
 inhibitor  
therapy.53,72
IIa B-R
In patients with ACS treated with DAPT  
after coronary stent implantation, who are  
not at high risk for bleeding complications  
and who do not have a history of stroke or 
TIA, it is reasonable to choose prasugrel over 
clopidogrel for maintenance P2Y
12
 inhibitor 
therapy.54,55
IIb A SR
In patients with ACS treated with coronary  
stent implantation who have tolerated  
DAPT without bleeding complication and  
who are not at high bleeding risk (eg, 
prior bleeding on DAPT, coagulopathy, 
oral anticoagulant use) continuation of 
DAPT for longer than 12 months may be 
reasonable.16,22–26,28,30,40,41,43,53,54,72
IIb C-LD
In patients with ACS treated with DAPT  
after DES implantation who develop a high 
risk of bleeding (eg, treatment with oral 
anticoagulant therapy), are at high risk  
of severe bleeding complication (eg, major 
intracranial surgery), or develop significant 
overt bleeding, discontinuation of P2Y
12
  
therapy after 6 months may be 
reasonable.17–21,34,36,37
III:  
Harm
B-R
Prasugrel should not be administered to patients 
with a prior history of stroke or TIA.54
SR indicates systematic review.
Recommendations for Duration of DAPT in Patients 
With ACS Treated With PCI (Continued)
CoR LoE Recommendations
Recommendation for Duration of DAPT in Patients 
With ACS Treated With CABG
CoR LoE Recommendation
I C-LD
In patients with ACS being treated with  
DAPT who undergo CABG, P2Y
12
 inhibitor 
therapy should be resumed after CABG to 
complete 12 months of DAPT therapy after 
ACS.52–54,118–120
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with an associated reduction in ischemic risk, can 
be achieved by blocking the P2Y12 receptor . In the 
CURE trial of patients with NSTE-ACS, the addition of 
clopidogrel (for up to 1 year) to aspirin monotherapy 
resulted in a 2 .1% absolute reduction in subsequent 
ischemic events but also a 1 .0% absolute increase in 
major bleeding .52 The majority of patients in this study 
were treated without revascularization, though benefit 
was observed both in those treated with revasculariza-
tion (PCI or CABG) and in those treated with medical 
therapy alone .51,52 Available evidence from this trial, 
as well as from PLATO53,71,72 and TRITON-TIMI 38,54,55 
supports DAPT duration of at least 12 months for patients 
with NSTE-ACS .
The results of the CURE trial52 and PCI-CURE analy-
ses of the CURE trial51 (Data Supplement 4) have been 
extrapolated to patients with STEMI on the basis of 
the consideration that NSTE-ACS and STEMI are both 
part of the spectrum of ACS and usually caused by 
coronary plaque rupture . Based on this consideration, 
as well as the results from the PLATO and TRITON-
TIMI 38 trials, it is recommended that patients with 
STEMI treated with coronary stent implantation or 
medical therapy alone (without revascularization or re-
perfusion therapy) be treated with DAPT for at least 
12 months .53–55,71,72 Ticagrelor is considered a P2Y12 
treatment option in patients with STEMI not treated 
with revascularization (or reperfusion therapy) on the 
basis of a similar extrapolation of the results of the 
“medically managed” patients with ACS in the PLATO 
trial .71 On the basis of CURE, PCI-CURE, PLATO, and 
TRITON-TIMI 38, clopidogrel, prasugrel, and ticagrelor 
Figure 4. Treatment algorithm for duration of P2y12 inhibitor therapy in patients with SIHD (without ACS within 
the past several years).  
Colors correspond to Class of Recommendation in Table 1 . Patients with a history of ACS >1 year prior who have since 
remained free of recurrent ACS are considered to have transitioned to SIHD . Arrows at the bottom of the figure denote that the 
optimal duration of prolonged DAPT is not established . Clopidogrel is the only currently used P2Y12 inhibitor studied in patients 
with SIHD undergoing PCI . Aspirin therapy is almost always continued indefinitely in patients with coronary artery disease . 
*High bleeding risk denotes those who have or develop a high risk of bleeding (eg, treatment with oral anticoagulant therapy) 
or are at increased risk of severe bleeding complication (eg, major intracranial surgery) . ACS indicates acute coronary syn-
drome; BMS, bare metal stent; CABG, coronary artery bypass graft surgery; DAPT, dual antiplatelet therapy; DES, drug-eluting 
stent; Hx, history; MI, myocardial infarction; PCI, percutaneous coronary intervention; SIHD, stable ischemic heart disease; and 
S/P, status post .
SIHD
No Hx of MI, PCI or 
recent (within 12 mo)
CABG
DES
6 mo
12 mo
S/P CABG BMS
No high risk of bleeding 
and no significant overt
 bleeding on DAPT
High 
bleeding 
risks* or 
significant 
overt 
bleeding
0 mo
Class IIb:
>6 mo may be reasonable 
Class IIb:
Discontinuation 
after 3 mo may 
be reasonable
3 mo
Prior MI, currently 
on DAPT
Class IIb:
Further 
continuation 
may be 
reasonable
Class III:
 No Benefit
Class IIb:
12 mo may be 
reasonable 
(clopidogrel)
Class I:
At least 1 mo 
(clopidogrel)
Class I:
At least 6 mo 
(clopidogrel)
1 mo
No high risk of bleeding
 and no significant overt 
bleeding on DAPT
Class IIb:
>1 mo may be reasonable 
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are all P2Y12 treatment options in patients with ACS 
treated with PCI .
In the CLARITY-TIMI 28 (Clopidogrel as Adjunctive 
Reperfusion Therapy—Thrombolysis In Myocardial In-
farction 28) trial, short-term treatment (up to 8 days) 
with clopidogrel (in addition to aspirin) in patients with 
STEMI undergoing fibrinolytic therapy improved TIMI 
flow grade in the culprit artery and decreased the com-
posite endpoint of cardiovascular death, reinfarction, 
or the need for urgent revascularization .142 In COM-
MIT (Clopidogrel and Metoprolol in Myocardial Infarc-
tion Trial) (93% with STEMI not managed with primary 
PCI), treatment for ≈2 weeks with clopidogrel (in ad-
dition to aspirin 162 mg) resulted in a 0 .9% absolute 
reduction of the 28-day composite endpoint of death, 
reinfarction, or stroke and a 0 .6% absolute reduction 
in death .140 A 1 .1% absolute risk reduction in the com-
posite endpoint was seen in the subgroup of patients 
who received fibrinolytic therapy . On the basis of these 
trials and extrapolation of the results of CURE, DAPT 
with aspirin and clopidogrel is recommended for a 
minimum of 14 days and ideally at least 12 months 
in patients with STEMI treated with fibrinolytic therapy 
(Data Supplement 4) .
As discussed in Section 3, treatment with prolonged 
(extended) DAPT beyond a minimum recommended du-
ration necessitates a fundamental tradeoff between 
decreasing ischemic risk (eg, MI and stent thrombosis) 
and increasing bleeding risk .16,24,28,30,34,36,37,46 In post-
MI patients, extended DAPT for approximately 18 to 
36 months leads to an absolute decrease in ischemic 
complications of ≈1% to 3% and an absolute increase 
in bleeding complications of ≈1% (Data Supplement 
4) .28,40,41,43,44 An analysis from the PEGASUS-TIMI 54 
trial found that the greatest reduction in ischemic 
events with prolonged DAPT in post-MI patients was 
in patients in whom P2Y12 inhibitor therapy either had 
not been discontinued or had been discontinued for 
≤30 days (absolute reduction in MACE: 1 .9 % to 2 .5%) . 
No benefit was seen in patients in whom P2Y12 inhibi-
tor therapy had been discontinued >1 year before 
enrollment in the study .42 Decisions about treatment 
with and duration of DAPT in patients with ACS require 
a thoughtful assessment of the benefit/risk ratio, in-
tegration of study data, and consideration of patient 
preference .
In patients treated with DAPT with high bleeding 
risk (eg, oral anticoagulation), increased risk of se-
vere bleeding complications (eg, major intracranial 
surgery), or significant overt bleeding, the benefit/risk 
ratio may favor shorter-than-recommended duration of 
DAPT .17–21,34,36
Recommendations for DAPT in patients with ACS 
treated with medical therapy alone, fibrinolytic therapy, 
PCI, and CABG are summarized in Figure 5 .
8. PERIoPERATIvE MANAGEMENT–TIMING 
oF ELECTIvE NoNCARDIAC SURGERy IN 
PATIENTS TREATED WITH PCI AND DAPT: 
RECoMMENDATIoNS
See Data Supplement 12 for evidence supporting these 
recommendations .
The timing of noncardiac surgery in patients treated 
with coronary stent implantation involves consideration 
of: (1) the risk of stent thrombosis (particularly if DAPT 
needs to be interrupted); (2) the consequences of de-
laying the desired surgical procedure; and (3) increased 
the intra- and peri-procedural bleeding risk and the con-
sequences of such bleeding if DAPT is continued15,147,148 
(Data Supplement 12) . DAPT significantly reduces the 
risk of stent thrombosis,50,51,94,95,99 and discontinuation 
of DAPT in the weeks after stent implantation is one of 
the strongest risk factors for stent thrombosis, with the 
magnitude of risk and impact on mortality rate inversely 
proportional to the timing of occurrence after the proce-
dure .145,149,150 Older observational studies found that the 
risk of stent-related thrombotic complications is highest 
Recommendations for Perioperative Management–
Timing of Elective Noncardiac Surgery in Patients 
Treated With PCI and DAPT
CoR LoE Recommendations
I B-NR
Elective noncardiac surgery should be delayed 
30 days after BMS implantation and optimally 6 
months after DES implantation.101–103,143–146
I C-EO
In patients treated with DAPT after coronary 
stent implantation who must undergo surgical 
procedures that mandate the discontinuation of 
P2Y
12
 inhibitor therapy, it is recommended that 
aspirin be continued if possible and the P2Y
12
 
platelet receptor inhibitor be restarted as soon as 
possible after surgery.
IIa C-EO
When noncardiac surgery is required in patients 
currently taking a P2Y
12
 inhibitor, a consensus 
decision among treating clinicians as to the relative 
risks of surgery and discontinuation or continuation 
of antiplatelet therapy can be useful.
IIb C-EO
Elective noncardiac surgery after DES implantation 
in patients for whom P2Y
12
 inhibitor therapy will 
need to be discontinued may be considered 
after 3 months if the risk of further delay of 
surgery is greater than the expected risks of stent 
thrombosis. 
III:  
Harm
B-NR
Elective noncardiac surgery should not be 
performed within 30 days after BMS implantation 
or within 3 months after DES implantation in 
patients in whom DAPT will need to be discontinued 
perioperatively.101–103,143–146
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in the first 4 to 6 weeks after stent implantation but con-
tinues to be elevated at least 1 year after DES place-
ment .101–103,149 Data from more recent large observational 
studies suggest that the time frame of increased risk of 
stent thrombosis is on the order of 6 months, irrespec-
tive of stent type (BMS or DES) .151–153 In a large cohort of 
patients from the Veterans Health Administration hospi-
tals, the increased risk of surgery for the 6 months after 
stent placement was most pronounced in those patients 
in whom the indication for PCI was an MI .146 An additional 
consideration, irrespective of the timing of surgery, is 
that surgery is associated with proinflammatory and pro-
thrombotic effects that may increase the risk of coronary 
thrombosis at the level of the stented vascular segment 
as well as throughout the coronary vasculature .154,155
Prior recommendations with regard to duration of 
DAPT9,104 and the timing of noncardiac surgery15,156 in pa-
tients treated with DES were based on observations of 
those treated with first-generation DES . Compared with 
first-generation DES, currently used newer-generation 
DES are associated with a lower risk of stent thrombosis 
and appear to require a shorter minimum duration of DAPT 
17,18,21,38,96,97 Several studies of DAPT duration in patients 
treated with newer-generation DES did not detect any dif-
ference in the risk of stent thrombosis between patients 
treated with 3 to 6 months of DAPT or patients treated 
with longer durations of DAPT (although these studies 
were underpowered to detect such differences)17–21 (Data 
Supplement 1) . Moreover, the safety of treating selected 
patients with newer-generation DES for shorter durations 
Figure 5. Treatment algorithm for duration of P2y12 inhibitor therapy in patients with recent ACS (NSTE-ACS or STEMI).  
Colors correspond to Class of Recommendation in Table 1 . Arrows at the bottom of the figure denote that the optimal duration 
of prolonged DAPT is not established . Aspirin therapy is almost always continued indefinitely in patients with coronary artery 
disease . *High bleeding risk denotes those who have or develop a high risk of bleeding (eg, treatment with oral anticoagulant 
therapy) or are at increased risk of severe bleeding complication (eg, major intracranial surgery) . ACS indicates acute coronary 
syndrome; BMS, bare metal stent; CABG, coronary artery bypass graft surgery; DAPT, dual antiplatelet therapy; DES, drug-
eluting stent; lytic, fibrinolytic therapy; NSTE-ACS, non–ST-elevation acute coronary syndrome; PCI, percutaneous coronary 
intervention; and STEMI, ST-elevation myocardial infarction .
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(3 or 6 months) of DAPT has been shown in a patient-
level analysis pooling 4 trials evaluating DAPT durations .34 
Furthermore, in the PARIS (Patterns of Nonadherence to 
Antiplatelet Regimens in Stented Patients) registry, inter-
ruption of DAPT according to physician judgment in pa-
tients undergoing surgery at any time point after PCI was 
not associated with an increased risk of MACE .145 On the 
basis of these considerations, the prior Class I recom-
mendation that elective noncardiac surgery in patients 
treated with DES be delayed 1 year15 has been modified 
to “optimally at least 6 months .” Similarly, the prior Class 
IIb recommendation that elective noncardiac surgery in 
patients treated with DES may be considered after 180 
days15 has been modified to “after 3 months .” Figure 6 
summarizes recommendations on timing of elective non-
cardiac surgery in patients with coronary stents .
The magnitude of incremental bleeding risk in patients 
treated with antiplatelet therapy who undergo surgery is 
uncertain .157,158 If P2Y12 inhibitor therapy needs to be held 
in patients being treated with DAPT after stent implanta-
tion, continuation of aspirin therapy if possible is recom-
mended, though this is based primarily on expert opinion . 
If a P2Y12 inhibitor has been held before a surgical pro-
cedure, therapy is restarted as soon as possible, given 
the substantial thrombotic hazard associated with lack 
of platelet inhibition early after surgery in patients with 
recent stent implantation . Although several small studies 
have used intravenous antiplatelet agents as a means of 
“bridging” in patients requiring temporary discontinuation 
of DAPT before surgery, there is no convincing clinical ev-
idence demonstrating the efficacy of bridging with either 
parenteral antiplatelet or anticoagulant therapy .159–163
Decisions about the timing of surgery and whether to 
discontinue DAPT after coronary stent implantation are 
best individualized . Such decisions involve weighing the 
particular surgical procedure and the risks of delaying 
Figure 6. Treatment algorithm for the timing of elective noncardiac surgery in patients with coronary stents.  
Colors correspond to Class of Recommendation in Table 1 . BMS indicates bare metal stent; DAPT, dual antiplatelet therapy; 
DES, drug-eluting stent; and PCI, percutaneous coronary intervention .
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the procedure, the risks of ischemia and stent thrombo-
sis, and the risk and consequences of bleeding . Given 
the complexity of these considerations, decisions are 
best determined by a consensus of the surgeon, anes-
thesiologist, cardiologist, and patient .
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